The client was an integrated pharmaceutical industry player from India that had recently acquired a Canadian company with radiopharmaceuticals in its product portfolio. This provided it with an opportunity to enter the Indian radiopharmaceutical business. The client wanted UC STRATEGY to conduct a detailed market assessment of radiopharmaceuticals and contrast agents for CT and MRI in the Indian market, as well as evaluate its feasibility based on the attractiveness of the market.
Our role was to provide a perspective on a market which was still in its nascent stages in India. We provided the following insights to our client:
- Perspective on the current market size, growth and outlook over next 5 years for key applications and modalities across India for radiopharmaceuticals, contrast agents for CT and MRI scans and radioimmunoassay kits
- Insight into the overall usage of radiopharmaceuticals in India – i.e. diagnostics vs. therapeutics
- Synthesis of opinions from key opinion leaders on the usage of radiopharmaceuticals and potential cannibalisation by modalities of one another
- An understanding of whether a radiopharmacy model is a need in India and its potential benefits
- Insight on the economics underlying this market
- View on the competitive landscape and the challenges it posed to our client
- Understanding of the regulatory framework from AERB (Atomic Energy Regulatory Board), laws and import duty structure, patents expiring for both radioisotopes and cold kits
The analysis revealed that our client could launch its products at a price point between two key leading competitors in the market. We also recommended that the client consider setting up a radiopharmacy. We cautioned the client, a large Indian MNC, to consider the material significance of the radiopharmaceutical market (given that it is nascent in India) before entering the space.